Sunday, February 04, 2007

Fetal medical non invasive procedures.

Researchers of the American Company Ravgen Inc's, led by Ravinder Dhallan, developed a blood test (treated with formaldehyde, that selects abundant fetal dna) , extracted of gestating mothers (first trimester of the pregnancy. Lancet, Journal of the American Medical Association). After extracting and processing samples of blood treated with formaldehyde the investigators found that these contained an average of 20.2% of fetal adn, compared with 7.7% of not treated samples. Fetal previous tests: fetal sonography, amniocentesis, biopsy of coriónic villous, blood of the umbilical cord are effective but also invasive and dangerous. According to Alan Cameron, consulting obstetrician of Queen Mother Elizabeth Hospital from Glasgow, all that one can make at the moment in sure and non invasive form is to identify blood fetal groups. Alastair Kent, director of Genetic Interest Group, said that it is a notable advancement that will give arguments to the gestating ones to decide on important aspects of their pregnancies.

Procedimientos médicos fetales no invasivos.

Investigadores de la firma Americana Ravgen Inc's, liderados por Ravinder Dhallan, desarrollaron un test sanguineo que selecciona abundante dna fetal a partir de muestras sanguineas (tratadas con formaldehído), extraidas de madres gestantes que cursaban el primer trimestre del embarazo (Lancet, Journal of the American Medical Association). Tras extraer y procesar muestras de sangre de gestantes tratadas con formaldehído los investigadores encontraron que estas contenian un promedio de 20.2 % de adn fetal, comparada con el 7.7 % de muestras no tratadas. Tests fetales previos : sonografia fetal, amniocentesis, biopsia de vellosidades coriónicas, sangre del cordón umbilical son eficaces pero tambien invasivos y peligrosos. Según Alan Cameron, obstetra consultante del Queen Mother Elizabeth Hospital de Glasgow, todo lo que se puede hacer actualmente en forma segura y no invasiva es identificar grupo sanguineos fetales. Alastair Kent, director del Genetic Interest Group, opino que se trata de un notable avance que dará argumentos a las gestantes para decidir sobre aspectos importantes de sus embarazos.

No comments: